Maravai LifeSciences Holdings Inc（MRVI）の財務MRVIMaravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings Inc (MRVI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nucleic Acid Production, accounting for 67.4% of total sales, equivalent to $34.67M. Another important revenue stream is Biologics Safety Testing. Understanding this composition is critical for investors evaluating how MRVI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Maravai LifeSciences Holdings Inc maintains a gross margin of 40.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25.78%, while the net margin is -42.05%. These profitability ratios, combined with a Return on Equity (ROE) of -32.90%, provide a clear picture of how effectively MRVI converts its operational activities into shareholder value.

In the context of the broader market, MRVI competes directly with industry leaders such as SEPN and XNCR. With a market capitalization of $1.97B, it holds a leading position in the sector. When comparing efficiency, MRVI's gross margin of 40.14% stands against SEPN's 100.00% and XNCR's 100.00%. Such benchmarking helps identify whether Maravai LifeSciences Holdings Inc is trading at a premium or discount relative to its financial performance.

Maravai's gross margin improved significantly to 40.14% in Q2 2026, up from 16.49% in Q1 2025, indicating a recovery in profitability. However, the company reported a net income loss of -12.42 million USD in Q2 2026, which shows ongoing challenges in achieving profitability.